Manisha Desai1, Vilija Joyce2, Eran Bendavid3, Richard A Olshen4, Mark Hlatky5, Adam Chow2, Mark Holodniy2, Paul Barnett2, Douglas K Owens6. 1. Quantitative Sciences Unit, Center for Biomedical Informatics Research, Department of Medicine Division of Biostatistics, Department of Health Research & Policy, Stanford University. 2. VA Palo Alto Health Care System. 3. Center for Primary Care and Outcomes Research, and Center for Health Policy Division of General Medical Disciplines, Department of Medicine. 4. Division of Biostatistics, Department of Health Research & Policy, Stanford University. 5. Division of Health Policy, Department of Health Research & Policy, Stanford University, Stanford, California. 6. VA Palo Alto Health Care System Center for Primary Care and Outcomes Research, and Center for Health Policy.
Abstract
BACKGROUND: To characterize the association of antiretroviral drug combinations on risk of cardiovascular events. METHODS: Certain antiretroviral medications for human immunodeficiency virus (HIV) have been implicated in increasing risk of cardiovascular disease. However, antiretroviral drugs are typically prescribed in combination. We characterized the association of current exposure to antiretroviral drug combinations on risk of cardiovascular events including myocardial infarction, stroke, percutaneous coronary intervention, and coronary artery bypass surgery. We used the Veterans Health Administration Clinical Case Registry to analyze data from 24 510 patients infected with HIV from January 1996 through December 2009. We assessed the association of current exposure to 15 antiretroviral drugs and 23 prespecified combinations of agents on the risk of cardiovascular event by using marginal structural models and Cox models extended to accommodate time-dependent variables. RESULTS: Over 164 059 person-years of follow-up, 934 patients had a cardiovascular event. Current exposure to abacavir, efavirenz, lamivudine, and zidovudine was significantly associated with increased risk of cardiovascular event, with odds ratios ranging from 1.40 to 1.53. Five combinations were significantly associated with increased risk of cardiovascular event, all of which involved lamivudine. One of these-efavirenz, lamivudine, and zidovudine-was the second most commonly used combination and was associated with a risk of cardiovascular event that is 1.60 times that of patients not currently exposed to the combination (odds ratio = 1.60, 95% confidence interval, 1.25-2.04). CONCLUSIONS: In the VA cohort, exposure to both individual drugs and drug combinations was associated with modestly increased risk of a cardiovascular event.
BACKGROUND: To characterize the association of antiretroviral drug combinations on risk of cardiovascular events. METHODS: Certain antiretroviral medications for human immunodeficiency virus (HIV) have been implicated in increasing risk of cardiovascular disease. However, antiretroviral drugs are typically prescribed in combination. We characterized the association of current exposure to antiretroviral drug combinations on risk of cardiovascular events including myocardial infarction, stroke, percutaneous coronary intervention, and coronary artery bypass surgery. We used the Veterans Health Administration Clinical Case Registry to analyze data from 24 510 patients infected with HIV from January 1996 through December 2009. We assessed the association of current exposure to 15 antiretroviral drugs and 23 prespecified combinations of agents on the risk of cardiovascular event by using marginal structural models and Cox models extended to accommodate time-dependent variables. RESULTS: Over 164 059 person-years of follow-up, 934 patients had a cardiovascular event. Current exposure to abacavir, efavirenz, lamivudine, and zidovudine was significantly associated with increased risk of cardiovascular event, with odds ratios ranging from 1.40 to 1.53. Five combinations were significantly associated with increased risk of cardiovascular event, all of which involved lamivudine. One of these-efavirenz, lamivudine, and zidovudine-was the second most commonly used combination and was associated with a risk of cardiovascular event that is 1.60 times that of patients not currently exposed to the combination (odds ratio = 1.60, 95% confidence interval, 1.25-2.04). CONCLUSIONS: In the VA cohort, exposure to both individual drugs and drug combinations was associated with modestly increased risk of a cardiovascular event.
Authors: W H Belloso; L C Orellana; B Grinsztejn; J S Madero; A La Rosa; V G Veloso; J Sanchez; R Ismerio Moreira; B Crabtree-Ramirez; O Garcia Messina; M B Lasala; J Peinado; M H Losso Journal: HIV Med Date: 2010-03-21 Impact factor: 3.180
Authors: Lisa I Backus; Sergey Gavrilov; Timothy P Loomis; James P Halloran; Barbara R Phillips; Pamela S Belperio; Larry A Mole Journal: J Am Med Inform Assoc Date: 2009-08-28 Impact factor: 4.497
Authors: Allison Martin; Mark Bloch; Janaki Amin; David Baker; David A Cooper; Sean Emery; Andrew Carr Journal: Clin Infect Dis Date: 2009-11-15 Impact factor: 9.079
Authors: Clay Bavinger; Eran Bendavid; Katherine Niehaus; Richard A Olshen; Ingram Olkin; Vandana Sundaram; Nicole Wein; Mark Holodniy; Nanjiang Hou; Douglas K Owens; Manisha Desai Journal: PLoS One Date: 2013-03-26 Impact factor: 3.240
Authors: Caroline A Sabin; Signe W Worm; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Christian Pradier; Ian Weller; Andrew N Phillips; Jens D Lundgren Journal: Lancet Date: 2008-04-02 Impact factor: 202.731
Authors: Gbolahan O Ogunbayo; Le Dung Ha; Qamar Ahmad; Naoki Misumida; Remi Okwechime; Ayman Elbadawi; Ahmed Abdel-Latif; C S Elayi; Susan Smyth; Franck Boccara; Adrian W Messerli Journal: J Gen Intern Med Date: 2019-11-11 Impact factor: 5.128
Authors: Richard A Elion; Keri N Althoff; Jinbing Zhang; Richard D Moore; Stephen J Gange; Mari M Kitahata; Heidi M Crane; Daniel R Drozd; James H Stein; Marina B Klein; Joseph J Eron; Michael J Silverberg; William C Mathews; Amy C Justice; Timothy R Sterling; Charles S Rabkin; Angel M Mayor; Daniel B Klein; Michael A Horberg; Ronald J Bosch; Oghenowede Eyawo; Frank J Palella Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731
Authors: Gbolahan O Ogunbayo; Katrina Bidwell; Naoki Misumida; Le Dung Ha; Ahmed Abdel-Latif; Claude S Elayi; Susan Smyth; Adrian W Messerli Journal: Clin Cardiol Date: 2018-04-19 Impact factor: 2.882